can you take semaglutide with fatty liver Active ingredient in weight loss drug Wegovy may help treat type of disease: Study Mechanisms of Non-alcoholic Fatty Liver

Medical Eligibility Criteria BMI Requirements (Same as In-Person): You qualify if: BMI 30 (obesity category), OR BMI 27 (overweight category) with at least one weight-related health condition Weight-Related Conditions: Type 2 diabetes or prediabetes Hypertension (high blood pressure) High cholesterol or dyslipidemia Obstructive sleep apnea Cardiovascular disease Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease Osteoarthritis worsened by weight Calculate Your BMI: BMI = (Weight in pounds / Height in inches) 703 Quick Reference: Age Requirements: Typically 18+ for adults Some medications approved for age 12+ (with parental consent) Contraindications (Cannot Prescribe If Present): Absolute Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnancy or planning pregnancy within 2 months Breastfeeding Previous severe allergic reaction to GLP-1 medications Relative Contraindications (May Preclude or Require Caution): History of pancreatitis Severe gastroparesis Active eating disorder (anorexia, bulimia) Severe kidney disease Active gallbladder disease Diabetic retinopathy (recent diagnosis) Medication Considerations May Require Dose Adjustments: Currently taking insulin On sulfonylureas (diabetes medications) Taking blood thinners (warfarin) Generally Compatible: Blood pressure medications Cholesterol medications Most antidepressants Thyroid medications Provider will review all current medications during consultation

Dutasteride is a 5-alpha-reductase inhibitor (5-ARI) indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) as monotherapy or in combination with tamsulosin

Last reviewed June 30, 2026

Ipamorelin works through a different door the ghrelin receptor which is why combining them or pairing one with CJC-1295 produces a stronger pulse than either alone

These adaptations can lead to a decrease in metabolic rate and an increase in hunger, making it harder to continue losing weight despite ongoing GLP-1 treatment